scholarly journals SHV-12, SHV-5, SHV-2a and VEB-1 extended-spectrum beta-lactamases in Gram-negative bacteria isolated in a university hospital in Thailand

2001 ◽  
Vol 48 (6) ◽  
pp. 839-852 ◽  
Author(s):  
A. Chanawong
2020 ◽  
Vol 4 (3) ◽  
pp. 230-241
Author(s):  
Olumuyiwa Alabi ◽  
Abiola Obisesan ◽  
Mary Taiwo ◽  
Rhoda Adewuyi

Extended-spectrum beta-lactamases (ESBLs) and metallo beta-lactamases (MBLs) are compromising the chemotherapeutic use of cephalosporins and carbapenems respectively. This study investigated the burden of ESBLs and MBLs co-production among multi-drug resistant (MDR) Gram-negative bacteria collected from two tertiary hospitals in Oyo State. A total of 240 non-duplicated clinical isolates of Escherichia coli, Klebsiella spp. and Pseudomonas spp. were collected from the Microbiology units of two tertiary hospitals in Oyo State and their identities authenticated using standard identification techniques. Antimicrobial susceptibility testing was carried out by disc-diffusion method and isolates exhibiting resistance to ≥3 classes of antibiotics selected as MDR strains. ESBL and MBL production was detected by double-disc synergy test (DDST) and combined-disc-diffusion test (CDDT) respectively. Selected beta-lactamase genes were detected by PCR, amplicons sent out for sequencing and phylogenetic tree of the sequences constructed using Mega X software. MDR was exhibited by 43.8% of the isolates. ESBLs and MBLs were produced by 32.4% and 7.6% of the MDR isolates respectively. Co-production of ESBL and MBL was observed in 6.7% of the MDR isolates. BlaCTX-M-15 (67.7%), blaTEM-1 (55.9%), blaSHV-1 (47.1%), co-existing blaTEM + blaSHV, blaTEM + blaCTX-M, blaCTX-M + blaSHV (each in 5.9%) and blaCTX-M +blaTEM + blaSHV (26.5%) were detected among the ESBL-producers. MBL genes were not detected among the MBL-producers. Only blaTEM-1 sequences showed two different claudes on the phylogenetic tree. The occurrence of MDR isolates co-harbouring different classes of beta-lactamse genes observed in this study is of public health concern and hence, requires stricter control of antibiotic use.


Author(s):  
Babafela Awosile ◽  
Michael Agbaje ◽  
Oluwawemimo Adebowale ◽  
Olugbenga Kehinde ◽  
Ezekiel Omoshaba

This review was carried out to identify different beta-lactamase resistance genes reported in published literature from Nigeria and to determine the proportion estimates of the important beta-lactamase resistance genes in Nigeria. Sixty-three (63) articles were included in this review based on the eligibility criteria. All the beta-lactamases reported were detected from the Gram-negative bacteria, most especially from Enterobacteriaceae (n=53). Thirty-six different beta-lactamase genes have been reported from Nigeria. These genes belong to the narrow-spectrum, AmpC, extended-spectrum, and carbapenemase beta-lactamase resistance genes. Eight (8) genes (blaDHA, blaCTXM-1, blaCTXM-14, blaGES-1, blaVEB-1, blaOXA-1, blaOXA-2, and blaTEM-1) were shared between animals and humans, 5 genes (blaSHV-1, blaSHV-2, blaSHV-11, blaSHV-12, and blaNDM-1) were common to both humans and environment while none of the genes was unique to both animals and environment. Four genes including blaCMY, blaTEM-1, blaAmpC, and internationally pandemic blaCTXM-15 gene were unique to animals, humans, and the environment. No carbapenemase gene was reported from animals yet. The pooled proportion estimate of ESBL genes in Nigeria was 31% (95% CI: 26-36%, P<0.0001), while the estimate of blaCTXM-15 gene in Nigeria was 46% (95% CI: 36-57%, P<0.0001). The proportion estimate of AmpC genes was 32% (95% CI: 11-52%, P<0.001), while the estimate for carbapenemases was 8% (95% CI: 5-12%, P<0.001). This study has provided information on the beta-lactamases distribution in Nigeria. This is necessary for a better understanding of molecular epidemiology of clinically important beta-lactamases especially the extended-spectrum beta-lactamases and carbapenemases in Nigeria.


Author(s):  
Florence Bose Omoregbe ◽  
Obasola Ezekiel Fagade

Extended Spectrum Beta-Lactamases (ESBLs) enzymes are produced by many Gram-negative bacteria to nearly all antibiotics. Clinical bacteria isolates were obtained from various clinical samples from the two healthcare facilities. Sewer wastewater and sediments were also collected from both hospitals using standard sampling techniques and bacteria isolated using pour plate technique. Multiple drug resistant patterns were determined using disc diffusion technique. Antibiotics sensitivity of the isolates was verified using disc diffusion method. Detection of ESBL producing bacteria was done using double disc synergy test. Data obtained were analysed using descriptive statistics. Clinical bacteria (403) were obtained, out of which 299 were confirmed Gram-negative, 218 from Federal Medical Centre (FMC) and 81 from Benue State Teaching Hospital (BSUTH). Thirty-nine Gram-negative bacteria were also isolated from the environmental samples. The ESBL producers in clinical isolates were 69 (FMC) and 42 (BSUTH) while in environmental isolates they were eight and four respectively. Out of a total of 338 environmental and clinical isolates from the two hospitals, 216 shown resistance/intermediate resistance to Ceftazidime. Of these 216, 123(36.39%) were positive for ESBLs production.- space From FMC, ESBLs producing bacteria are highly sensitive to imipenem with sensitivity frequency of 62 while they were highly resistant to ceftazidime with a frequency of 52. Age groups 0-5 had the highest percentage distribution of 21.43% and 10.14% from BSUTH and FMC respectively. ESBLs producing bacteria showed multidrug resistance.


1997 ◽  
Vol 8 (3) ◽  
pp. 147-153 ◽  
Author(s):  
Kevin R Forward ◽  
Donald E Low ◽  
Michel Laverdiere ◽  
Robert Rennie ◽  
Andrew E Simor ◽  
...  

OBJECTIVES: To compare the activity of piperacillin-tazobactam with piperacillin and other parenterally administered antibiotics against aerobic Gram-negative bacilli and Gram-positive cocci isolated from across Canada, and to determine the prevalence of resistance mediated by extended-spectrum cephalosporinases.METHODS: Sixty-one laboratories participated. Disk diffusion testing was performed in accordance with methods outlined by the National Committee for Clinical Laboratory Standards. Susceptibilities were performed on 8206 strains.Escherichia coliandKlebsiella pneumoniaewith reduced susceptibilities to third-generation cephalosporins were screened for extended-spectrum beta-lactamases (ESBLs).RESULTS: Piperacillin-tazobactam was active against 92% of the strains, piperacillin against 81% and ticarcillin-clavulanic acid against 88%. Few differences were observed in the relative susceptibility of strains from teaching or community hospitals, from different anatomic sites or from different regions of the country. Aerobic Gram-negative bacilli tested tended to be more susceptible to all the agents than was recently reported in a similar American study. Only 43% ofEnterococcus faeciumwere susceptible to ampicillin and 42% to piperacillin piperacillin with and without tazobactam. Only two enterococcal strains were resistant to vancomycin, and 19 had intermediate zone sizes. Of the 10 strains ofE coliand eight strains ofK pneumoniaewith reduced susceptibility to extended spectrum cephalosporins, only one demonstrated typical ESBL activity.CONCLUSIONS: Canadian aerobic Gram-positive cocci and Gram-negative bacilli remain highly susceptible to many currently available antibiotics. The findings confirm a broad spectrum of activity of piperacillin-tazobactam and indicate that the pattern of susceptibility is quite uniform from different body sites, in both teaching and community hospitals, and across the country.


Sign in / Sign up

Export Citation Format

Share Document